ABSTRACT: Self-emulsifying drug delivery system (SEDDS) is successfully used to improve the aqueous solubility and oral bioavailability of the poorly aqueous soluble drugs. Atorvastatin calcium (ATV), a poorly aqueous soluble drug having low oral bioavailability, was the model drug for this study. The aim of this study was to find out the suitable lipid and surfactant which can be used in formulation of ATV-SEDDS and this was done using ternary phase diagram, an important tool used very essentially in optimizing SEDDS formulations. 
INTRODUCTION
Atorvastatin calcium (ATV), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is a plasma lipid regulating agent. ATV has therapeutic applications in hyperlipidemia and cardiovascular events.
ATV ([R-(R,R*)-2-(4-fluorophenyl)-β, γ-dihydroxy-5-(1-methylethyl) -3-phenyl-4-(phenylamino)
carbonyl]-1H-pyrrol-1-heptanoic acid, hemi-calcium salt) is a white to off-white crystalline powder. The empirical formula of atorvastatin calcium is (C 33 H 34 FN 2 O 5 ) 2 Ca 2+ ·3H 2 O with a molecular weight of 1209.42. The oral bioavailability of atorvastatin is limited by factors such as the membrane permeability, the solubility, the dissolution rate of the drug and so on. Specially, the solubility and the dissolution rate of a sparingly water soluble drug is a critical factor for its oral bioavailability. Oral bioavailability of ATV is only 12% and its poor solubility in water and high presystemic clearance (> 80%) have been attributed to its poor bioavailability. 1 According to the USP, very slightly soluble drugs are defined as solubility value of 0.1 mg/ml to 1 mg/ml; insoluble or practically insoluble drugs are those having a solubility value of < 0.1 mg/ml (100 µg/ml). According to biopharmaceutical classification system (BCS), low solubility means drug will not dissolve in 250 mL of buffer solution throughout the pH range of 1 to 8. According to Lindenberg et al. (2004) , 2 low solubility means dissolution time of dose will be greater than normal transit time through normal absorption regions of GI tract.
ATV is insoluble in aqueous solution of pH ≤ 4.0 and below; it is very slightly soluble in water and slightly soluble at pH 7.4 phosphate buffers and acetonitrile, slightly soluble in ethanol and freely soluble in methanol. The intestinal permeability of ATV is high at the physiologically intestinal pH of 6.0-6.5.
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The purpose of this present study was to investigate and generate the solubility data of ATV in different lipid/surfactant mixtures where lipid/surfactant ratios were permutated to generate the maximum solubility data. Ternary Phase Diagram was used to present the solubility profile of the drug where amount of atorvastatin, lipid and surfactant were the three variables.
MATERIALS AND METHODS
Atorvastatin calcium was purchased from Ranbaxy, India. Oleic acid (Merck, Germany), Capmul PG 8 (Abitec Corporation, USA), Tween 20 and 80 (BDH Chemicals Ltd, England) was received as gift. Cremophor CO 40, Cremophor CO 60, Cremophor EL, Cremophor RH 40, Cremophor RH 60 were also received as gifts from BASF (BASF, Germany). Solubility study of atorvastatin in different excipients. Mixtures of lipids (Capmul PG 8 or Oleic acid) and surfactants (Tween 20, Tween 80, Cremophor CO 40, Cremophor CO 60, Cremophor EL, Cremophor RH 40, Cremophor RH 60) at different ratios were prepared in captubes. Briefly, ATV was gradually added in each of the captube up to the maximum solubility capacity of lipid/surfactant mixture. After each increment, the captube containing lipid/surfactant/drug mixture was heated in sealed condition in a water bath at ≤ 90°C for ≤5 minutes to facilitate the solubilization of ATV. Solubility points (percentage of lipid, surfactant and ATV) were then plotted in a ternary phase diagram. Few of the major points in the ternary phase diagram considered during solubility study and their corresponding result are shown in table 1-14. After connecting the solubility points in the phase diagram, a soluble area of ATV was found.
RESULTS AND DISCUSSION
This research study was conducted with the aim of generating some solubility data of ATV in lipid/surfactant mixture. In the ternary phase diagram, individual point (X, Y, Z) representing the weight percentage of lipid, drug, and surfactant was considered to check whether atorvastatin is soluble/insoluble at that particular point. Only the major solubility points of the drug and those, near the soluble/insoluble boundary area of the diagram, are shown in table 1-14. Soluble  II  90  0  10  Soluble  III  80  0  20  Soluble  IV  70  0  30  Soluble  V  80  10  10  Soluble  VI  70  20  10  Soluble  VII  70  10  20  Soluble  VIII  60  30  10  Soluble  IX  60  20  20  Soluble  X  50  40  10  Soluble  XI  40  50  10  Soluble  XII  30  60  10  Soluble  XIII  20  70  10  Soluble  XIV  10  80  10  Soluble  XV  0  90  10  Soluble  XVI  30  50  20  Insoluble  XVII  0  80  20  Insoluble  XVIII  40  40  20 Insoluble I  99  0  1  Soluble  II  90  0  10  Soluble  III  80  0  20  Soluble  IV  70  0  30  Soluble  V  80  10  10  Soluble  VI  70  20  10  Soluble  VII  70  10  20  Soluble  VIII  60  30  10  Soluble  IX  60  20  20  Soluble  X  50  40  10  Soluble  XI  40  50  10  Soluble  XII  30  60  10  Soluble  XIII  20  70  10  Soluble  XIV  10  80  10  Insoluble  XV  0  90  10  Insoluble  XVI  30  50  20  Insoluble  XVII  0  80  20  Insoluble  XVIII  40  40  20  Insoluble In the solubility phase diagrams, darker regions indicate soluble area for ATV. Two lipids (Capmul PG 8 and Oleic acid) and seven different surfactants of two particular groups (polyoxyethylene castor oil derivatives and polyoxyethylene sorbitan fatty acid esters) were used. I  99  0  1  Soluble  II  90  0  10  Soluble  III  80  0  20  Insoluble  IV  70  0  30  Insoluble  V  80  10  10  Soluble  VI  70  20  10  Soluble  VII  70  10  20  Insoluble  VIII  60  30  10  Soluble  IX  60  20  20  Insoluble  X  50  40  10  Soluble  XI  40  50  10  Soluble  XII  30  60  10  Soluble  XIII  20  70  10  Soluble  XIV  10  80  10  Soluble  XV  0  90  10  Soluble  XVI  30  50  20  Insoluble  XVII  0  80  20  Soluble  XVIII  40  40 20 Insoluble I  99  0  1  Soluble  II  90  0  10  Soluble  III  80  0  20  Soluble  IV  70  0  30  Soluble  V  80  10  10  Soluble  VI  70  20  10  Soluble  VII  70  10  20  Soluble  VIII  60  30  10  Soluble  IX  60  20  20  Soluble  X  50  40  10  Soluble  XI  40  50  10  Soluble  XII  30  60  10  Soluble  XIII  20  70  10  Soluble  XIV  10  80  10  Soluble  XV  0  90  10  Soluble  XVI  30  50  20  Insoluble  XVII  0  80  20  Insoluble  XVIII  40  40  20  Insoluble Figures 1-7 show the ternary phase diagrams for ATV solubility. Figure 1 shows the solubility diagram for Cremophor EL. Better solubility was achieved while this surfactant was mixed with oleic acid. Figure 2 shows the solubility diagram of Cremophor CO 40. In this case also, oleic acid/Cremophor CO 40 mixture showed better solubility than Capmul PG 8/Cremophor CO 40 mixture. Similarly, figure 3, figure 4, figure 5 , figure  6 I  90  0  10  Soluble  II  80  0  20  Insoluble  III  80  10  10  Soluble  IV  70  10  20  Insoluble  V  70  20  10  Soluble  VI  60  30  10  Soluble  VII  60  20  20  Insoluble  VIII  50  40  10  Soluble  IX  50  30  20  Insoluble  X  40  50  10  Soluble  XI  40  40  20  Soluble  XII  30  50  20  Soluble  XIII  10  60  30  Soluble  XIV  0  60  40  Insoluble  XV  0  64  36  Soluble  XVI  20  50  30  Insoluble A wide variety of lipids are available for the development of oral lipid-based formulations including long chain and medium chain triglycerides, propylene glycol esters, mono and diglycerides of medium chain and long chain fatty acids, various lipid mixtures, and so on. 5, 6 Adding to the diversity, the fatty acid components of the lipids can be either saturated or unsaturated, varying the field even more. According to Cannon and Long (2008) 6 , lipids that Soluble  IV  64  0  36  Soluble  V  60  0  40  Insoluble  VI  60  10  30  Soluble  VII  50  10  40  Insoluble  VIII  50  20  30  Soluble  IX  40  20  40  Insoluble  X  40  30  30  Soluble  XI  30  30  40  Insoluble  XII  30  40  30  Soluble  XIII  0  60  40  Insoluble  XIV  10  60  30  Soluble  XV  0  64 36 Soluble I  90  0  10  Soluble  II  80  0  20  Insoluble  III  80  10  10  Soluble  IV  70  20  10  Soluble  V  70  10  20  Insoluble  VI  60  30  10  Soluble  VII  60  20  20  Insoluble  VIII  50  40  10  Soluble  IX  50  30  20  Insoluble  X  40  50  10  Soluble  XI  40  40  20  Insoluble  XII  30  60  10  Soluble  XIII  30  50  20  Insoluble  XIV  20  70  10  Soluble  XV  20  60  20  Insoluble  XVI  10  80  10  Soluble  XVII  10  70  20  Insoluble  XVIII  0  80  20  Soluble  XIX  0  79 21 Insoluble I  90  0  10  Soluble  II  80  0  20  Soluble  III  70  0  30  Soluble  IV  60  0  40  Insoluble  V  67  33  0  Soluble  VI  60  10  30  Soluble  VII  50  20  30  Soluble  VIII  40  30  30  Insoluble  IX  40  40  20  Soluble  X  30  40  30  Insoluble  XI  30  50  20  Soluble  XII  20  50  30  Insoluble  XIII  20  60  20  Soluble  XIV  10  60  30  Insoluble  XV  10  70  20  Soluble  XVI  0  70  30  Insoluble  XVII  0  80 20 Soluble I  90  0  10  Soluble  II  80  0  20  Insoluble  III  80  10  10  Soluble  IV  70  10  20  Insoluble  V  70  20  10  Soluble  VI  60  20  20  Insoluble  VII  60  30  10  Soluble  VIII  50  30  20  Insoluble  IX  50  40  10  Soluble  X  40  40  20  Insoluble  XI  40  50  10  Soluble  XII  30  50  20  Insoluble  XIII  30  60  10  Soluble  XIV  20  60  20  Soluble  XV  10  70  20  Soluble  XVI  0  80  20  Soluble  XVII  0  70  30  Insoluble  XVIII  0  73  27  Soluble have fatty acid chains of 14-20 carbons are considered long chain, while those with 6-12 carbons are medium chain. Unless they consist of unsaturated fatty acid chains, the long-chain glycerides are usually solid at room temperature and, therefore, may I  90  0  10  Soluble  II  80  0  20  Soluble  III  70  0  30  Soluble  IV  60  0  40  Insoluble  V  65  0  35  Soluble  VI  60  10  30  Soluble  VII  50  20  30  Soluble  VIII  40  30  30  Soluble  IX  30  40  30  Insoluble  X  30  42  28  Soluble  XI  20  50  30  Insoluble  XII  20  60  20  Soluble  XIII  10  60  30  Insoluble  XIV  10  70  20  Soluble  XV  0  70  30  Insoluble  XVI  0  73 27 Soluble I  90  0  10  Soluble  II  80  0  20  Insoluble  III  70  20  10  Soluble  IV  70  10  20  Insoluble  V  60  20  20  Insoluble  VI  60  21  19  Soluble  VII  50  30  20  Soluble  VIII  40  30  30  Insoluble  IX  40  40  20  Soluble  X  30  40  30  Insoluble  XI  30  50  20  Soluble  XII  20  50  30  Insoluble  XIII  20  60  20  Soluble  XIV  10  60  30  Insoluble  XV  10  70  20  Soluble  XVI  0  70  30  Soluble  XVII  0  60  40  Insoluble  XVIII  0  68  32  Soluble not be suitable for dissolving drugs. Further, longchain glycerides which exist as liquids at room temperature (e.g., corn oil, sesame oil, peanut oil, olive oil, soybean oil, etc.) have been reported to have lower drug solubilities than medium-chain I  90  0  10  Soluble  II  80  0  20  Soluble  III  70  0  30  Soluble  IV  60  0  40  Insoluble  V  65  0  35  Soluble  VI  60  10  30  Soluble  VII  50  20  30  Soluble  VIII  40  30  30  Soluble  IX  30  40  30  Soluble  X  20  50  30  Soluble  XI  10  60  30  Soluble  XII  0  70  30  Insoluble  XIII  0  71 29 Soluble Figure 1 . Solubility phase diagram of ATV using Cremophor EL glycerides. 7, 8 Modified or hydrolyzed vegetable oils have been widely used since these excipients form good emulsification system with a large number of surfactants approved for oral administration and exhibit better drug solubility properties. [9] [10] [11] But natural long chain derivatives like oleic acid, which can be defined as amphiphilic compounds with surfactant properties, are progressively and effectively replacing the regular medium chain triglyceride lipids in the self-emulsifying formulations (SEFs). 9, 12, 13 The second lipid compound was Capmul PG 8 which is a propylene glycol monoester or propylene glycol monocaprylate of C8 fatty acids. It is a synthetic medium chain lipid and is a good choice of excipient in oral-lipid based formulations. Due to its lipophilic hydrophiliclipophilic balance (HLB) value of 5.0 and evidences of successful application in SEFs, 14, 15 it was considered to be used as lipid component in our study. As part of an ongoing research to optimizing some novel SEDDS formulations, it was tried to find out the best combination of lipid-surfactant mixture with respect to maximum ATV solubility since lipid/surfactant/drug ratio plays the pivotal role in the development of SEDDS. 16 However, more than 15% ATV was found to be dissolved in case of all the combinations of lipid/surfactant mixture. Amount of ATV dissolved in either single excipient or in combination of lipid/surfactant was found as maximum as 18% (wt/wt) for Cremophor EL and Cremophor CO 40, 20% (wt/wt) for Cremophor CO 60 and Cremophor RH 60, 30% (wt/wt) for Tween 20, up Among the non-ionic hydrophilic polysorbates, Tween 80 (polyoxyethylene 20 oleate) is the most widely used one. Due to its hydrophilic HLB value of 15.0, a good number of research works have been reported about the suitability, efficiency and compatibility of Tween 80 for using it in oral lipid based formulations. 9, [19] [20] [21] [22] 
CONCLUSION
It can be inferred from the obtained results that atorvastatin solubility may be improved by using different lipid/non-ionic hydrophilic surfactants where the lipid/surfactant ratio should be maintained at the optimum level. It has been shown by the ternary phase diagram that either Oleic acid or Capmul PG 8 can be a good choice of lipid in oral lipid-based formulations where either of the Cremophor RH grades (Cremophor RH 40 and Cremophor RH 60) or Tween grades (Tween 20, Tween 80) may be used as the surfactant.
